Tumor Cell Programmed Death Ligand 1-Mediated T Cell Suppression Is Overcome by Coexpression of CD80

Documenti analoghi

• Lung cancer patients’ CD4(+) T cells are activated in vitro by MHC II cell-based vaccines despite the presence of myeloid-derived suppressor cells
  di: Srivastava, Minu K., et al.
  Pubblicazione: (2008)
• Uveal melanoma cell-based vaccines express MHC II molecules that traffic via the endocytic and secretory pathways and activate CD8(+) cytotoxic, tumor-specific T cells
  di: Bosch, Jacobus J., et al.
  Pubblicazione: (2009)
• Soluble CD80 Restores T Cell Activation and Overcomes Tumor Cell Programmed Death Ligand-1-mediated Immune Suppression()
  di: Haile, Samuel T., et al.
  Pubblicazione: (2013)
• MHC II Lung Cancer Vaccines Prime and Boost Tumor-specific CD4(+) T Cells that Cross-React with Multiple Histologic Subtypes of Non-small Cell Lung Cancer Cells
  di: Srivastava, Minu K., et al.
  Pubblicazione: (2010)
• The absence of invariant chain in MHC II cancer vaccines enhances the activation of tumor-reactive type 1 CD4(+) T lymphocytes
  di: Thompson, James A., et al.
  Pubblicazione: (2007)